Xilio Therapeutics, Inc. (XLO) Insider Trading Activity

NASDAQ$7.99
Market Cap
$52.54M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
302 of 870
Rank in Industry
170 of 505

Largest Insider Buys in Sector

$376M
$350M
$215M
$107M
$100M
$99M

XLO Insider Trading Activity

XLO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$116,715
4
67
Sells
$5,696
2
33

Related Transactions

Shannon James Samueldirector
3
$92,035
0
$0
$92,035
Russo RenePRESIDENT AND CEO
1
$24,680
0
$0
$24,680
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
0
$0
1
$1,174
$-1,174
Frankenfield Christopher JamesChief Financial Officer
0
$0
1
$4,522
$-4,522

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

Insider Activity of Xilio Therapeutics, Inc.

Over the last 12 months, insiders at Xilio Therapeutics, Inc. have bought $116,715 and sold $5,696 worth of Xilio Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Xilio Therapeutics, Inc. have bought $8.48M and sold $6,184 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Shannon James Samuel (director) — $92,035. Russo Rene (PRESIDENT AND CEO) — $24,680.

The last purchase of 5,000 shares for transaction amount of $43,950 was made by Shannon James Samuel (director) on 2026‑03‑26.

List of Insider Buy and Sell Transactions, Xilio Therapeutics, Inc.

2026-03-26PurchaseShannon James Samueldirector
5,000
0.0965%
$8.79
$43,950
-4.15%
2026-01-02SaleFrankenfield Christopher JamesChief Financial Officer
7,030
0.0135%
$0.64
$4,522
-12.29%
2026-01-02SaleBrennan Kevin M.SVP, FINANCE AND ACCOUNTING
1,826
0.0035%
$0.64
$1,174
-12.29%
2025-06-17PurchaseShannon James Samueldirector
25,000
0.05%
$0.69
$17,215
0.00%
2025-06-16PurchaseRusso RenePRESIDENT AND CEO
36,289
0.0695%
$0.68
$24,680
-3.02%
2025-06-16PurchaseShannon James Samueldirector
45,000
0.0869%
$0.69
$30,870
-3.02%
2025-01-02SaleFrankenfield Christopher JamesChief Financial Officer
6,954
0.0147%
$0.98
$6,841
-30.84%
2025-01-02SaleBrennan Kevin M.SVP, FINANCE AND ACCOUNTING
1,803
0.0038%
$0.98
$1,774
-30.84%
2024-12-18PurchaseGILEAD SCIENCES, INC.10 percent owner
1.76M
4.8987%
$1.04
$1.83M
-13.44%
2024-04-02PurchaseGILEAD SCIENCES, INC.10 percent owner
485,250
0.9047%
$0.76
$368,790
-35.81%
2024-02-08SaleAtlas Venture Fund XI, L.P.10 percent owner
1,000
0.0034%
$0.64
$640
+57.38%
2024-01-12SaleAtlas Venture Fund XI, L.P.10 percent owner
2,100
0.0088%
$0.83
$1,743
+25.17%
2024-01-11SaleAtlas Venture Fund XI, L.P.10 percent owner
2,135
0.0083%
$0.87
$1,857
+14.46%
2021-12-10PurchaseBain Capital Life Sciences Investors, LLC10 percent owner
25,000
0.0858%
$9.65
$241,202
-70.24%
2021-12-09PurchaseBain Capital Life Sciences Investors, LLC10 percent owner
4,011
0.0145%
$9.84
$39,485
-69.23%
2021-12-08PurchaseBain Capital Life Sciences Investors, LLC10 percent owner
13,458
0.0484%
$9.62
$129,474
-68.51%
2021-10-26PurchaseSV7 Impact Medicine Fund LP10 percent owner
312,500
1.1398%
$16.00
$5M
-76.08%
2021-10-26PurchaseRiverVest Venture Fund IV, L.P.10 percent owner
250,000
0.9119%
$16.00
$4M
-76.08%
2021-10-26PurchaseRock Springs Capital Management LP10 percent owner
500,000
1.8238%
$16.00
$8M
-76.08%
2021-10-26PurchaseFlynn James E10 percent owner
387,500
1.4134%
$16.00
$6.2M
-76.08%
Total: 22
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Russo RenePRESIDENT AND CEO
281172
4.2763%
$2.25M10
Frankenfield Christopher JamesChief Financial Officer
24766
0.3767%
$197,880.3402
Shannon James Samueldirector
10000
0.1521%
$79,900.0030
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
6371
0.0969%
$50,904.2902
GILEAD SCIENCES, INC.10 percent owner
9105451
138.483%
$72.75M20
Bain Capital Life Sciences Investors, LLC10 percent owner
2805413
42.667%
$22.42M30
<0.0001%
SV7 Impact Medicine Fund LP10 percent owner
1613632
24.5414%
$12.89M10
<0.0001%
RiverVest Venture Fund IV, L.P.10 percent owner
1441444
21.9226%
$11.52M10
<0.0001%
Rock Springs Capital Management LP10 percent owner
1256472
19.1094%
$10.04M10
<0.0001%
Flynn James E10 percent owner
1143972
17.3984%
$9.14M10
<0.0001%
BAY CITY CAPITAL LLC10 percent owner
1129490
17.1782%
$9.02M10
<0.0001%
Atlas Venture Fund XI, L.P.10 percent owner
734546
11.1716%
$5.87M13
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$2,542,362
111
11.81%
$52.32M
$155,630,608
79
-24.53%
$52.39M
$693,326
47
-16.18%
$51.71M
$4,898,715
46
40.75%
$58.95M
$24,478,755
37
-34.59%
$57M
$30,257,839
29
-15.72%
$56.43M
$226,127
22
-27.62%
$50.24M
$17,594,514
16
-20.37%
$61.45M
$277,862
15
59.79%
$57.18M
$13,486,672
11
82.26%
$45.25M
Xilio Therapeutics, Inc.
(XLO)
$31,610,161
9
-73.83%
$52.54M
$45,000,000
6
-31.22%
$53.78M
$106,599,960
6
-7.63%
$58.13M
$208,889
5
44.22%
$46.61M
$762,555
4
-34.52%
$59.47M
$67,369,250
3
-22.09%
$45.44M
$19,175,155
2
40.00%
$61.2M
$4,999,995
1
-67.50%
$52.26M
$150,000
1
5.48%
$51.93M

XLO Institutional Investors: Active Positions

Increased Positions16+36.36%20M+98.53%
Decreased Positions14-31.82%1M-5.46%
New Positions11New17MNew
Sold Out Positions9Sold Out892,665Sold Out
Total Postitions46+4.55%40M+93.07%

XLO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Gilead Sciences, Inc.$6,119.0017.18%9.11M00%2025-09-30
Bain Capital Life Sciences Investors, Llc$3,069.008.62%4.57M00%2025-09-30
Merck & Co., Inc.$997.002.8%1.48M00%2025-09-30
Vanguard Group Inc$844.002.37%1.26M+104,669+9.09%2025-09-30
Morgan Stanley$646.001.82%961,917-482,409-33.4%2025-09-30
Aju Ib Investment Co., Ltd.$449.001.26%667,74200%2025-09-30
Fmr Llc$344.000.97%511,82000%2025-09-30
Geode Capital Management, Llc$221.000.62%328,972-40,688-11.01%2025-09-30
Squarepoint Ops Llc$221.000.62%328,794+93,338+39.64%2025-09-30
Trustees Of Columbia University In The City Of New York$168.000.47%249,63500%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.